Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission has asked the Committee for Medicinal Products for Human Use (CHMP) to consider two ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

One recent analysis found that, over the course of three years, people taking semaglutide (the compound in Ozempic and the weight loss drug Wegovy) were about 40 to 70 percent less likely to be ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

Topline data were published from a phase 2b/3 study evaluating blarcamesine for the treatment of early Alzheimer disease.

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

A major trial in frontotemporal dementia patients has found that oxytocin can help improve symptoms of apathy. A new study led by Western researchers suggests that frequent treatment with intranasal o ...

The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...

One London clinic has become the first in Europe to offer the drug privately for an 'eye-watering' annual sum, after the NHS ...

for early Alzheimer’s disease (AD). This decision may simplify the treatment process for patients and care partners. LEQEMBI, designed for patients with mild cognitive impairment (MCI) or mild ...